Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
68Ga-DOTA-NI-FAPI04 PET/CT in Cancer
NCT06455761Phase 1Recruiting
- Sponsor
- The First Hospital of Fujian Medical University
- Start
- Apr 2024
- Primary completion
- Apr 2025
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, open-label trial of 68Ga-DOTA-NI-FAPI04 in solid tumor (2 arms), sponsored by The First Hospital of Fujian Medical University. Primary endpoint: Diagnostic value at 3 months. Started Apr 2024; status: recruiting.
02
Drugs
68Ga-DOTA-NI-FAPI04
03
Conditions
solid tumor
Beyond the preview
Go deeper on NCT06455761.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06455761.